<DOC>
	<DOCNO>NCT00005601</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody , rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining combination chemotherapy monoclonal antibody therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus rituximab treating patient relapse non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Rituximab Treating Patients With Relapsed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate cisplatin , cytarabine , dexamethasone ( DHAP ) plus rituximab patient relapse CD20+ B-cell non-Hodgkin 's lymphoma . - Determine percentage patient able proceed transplant two course treatment regimen . - Determine duration response overall survival patient proceed transplant two course treatment regimen . OUTLINE : Patients receive rituximab IV day 1 , 8 , 15 , 22 first course . Patients receive dexamethasone orally IV day 1-4 , cisplatin IV continuously 24 hour day 1 , cytarabine IV 3 hour every 12 hour 2 dos day 2 , sargramostim ( GM-CSF ) subcutaneously day 3-12 blood count recover . Chemotherapy repeat every 21 day 2 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 17-50 patient accrue study within 11 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm CD20+ Bcell nonHodgkin 's lymphoma Relapsed follow chemotherapy eligible platinumcontaining regimen Measurable disease Must least 1.5 x 1.5 cm PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 75,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 1.5 time upper limit normal Cardiovascular : No uncontrolled hypertension Other : HIV negative No active malignancy No uncontrolled diabetes mellitus No uncontrolled peptic ulcer disease No uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>